Enzyme replacement therapies for lysosomal storage disorders;Thérapies enzymatiques substitutives des maladies lysosomales

Medecine/Sciences

Volumn 21, Issue SPEC. ISS. NOV., 2005, Pages 77-83

  Germain, Dominique P ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE; CHAPERONE; DERMATAN SULFATE; GLYCOGEN; LARONIDASE; N ACETYLGALACTOSAMINE 4 SULFATASE;

CENTRAL NERVOUS SYSTEM DISEASE; CONFERENCE PAPER; ENZYME DEFICIENCY; ENZYME REPLACEMENT; FABRY DISEASE; GAUCHER DISEASE; GENE MUTATION; GLYCOGEN STORAGE DISEASE TYPE 2; GLYCOSAMINOGLYCAN METABOLISM; HEART MUSCLE; HEPATOMEGALY; HISTORY OF MEDICINE; HUMAN; HURLER SYNDROME; LYSOSOME STORAGE DISEASE; MAROTEAUX LAMY SYNDROME; MUCOPOLYSACCHARIDOSIS; MUSCLE CELL; NIEMANN PICK DISEASE; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN STABILITY; RESPIRATORY FUNCTION; SKELETAL MUSCLE;

EID: 29944443176     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/20052111s77     Document Type: Conference Paper

References (30)

1. Hers HG. Alpha-glucosidose deficiency in generalized glycogen storage disease (Pompe's disease). Biochem J 1963; 86: 11-6.
2. Brady RO, Kanfer JN, Shapiro D. Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's disease. Biochem Biophys Res Commun 1965; 18: 221-5.
3. Neufeld EF, Fratantoni JC. Inborn errors of mucopolysaccharide metabolism. Science 1970; 169: 141-6.
4. Mistry PK. Gaucher's disease: a model for modern management of a genetic disease. J Hepatol 1999; 30 (suppl 1): 1-5.
5. Germain DP. Gaucher's disease: a paradigm for interventional genetics. Clin Genet 2004; 65: 77-86
6. Stahl P, Schlesinger PH, Sigardson E, et al. Receptor-mediated pinocytosis of mannose glycoconjugates by macrophages: characterization and evidence for receptor recycling. Cell 1980; 19: 207-15.
7. Barton NW, Furbish FS, Murray GJ, et al. Therapeutic response to intravenous infusions of glucacerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci USA 1990; 87: 1913-6.
8. Grabowski G, Barton NM, Pastores G, et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995; 122: 33-9.
9. Pastores G, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004; 41: 4-14.
10. Weinreb NJ, Aggio MC, Andersson HC, et al. Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol 2004; 41: 15-22.
11. Hollak CM, Aerts J, Goudsmit R, et al. Individualised low-dose alglucerase therapy for type 1 Gaucher's disease. Lancet 1995; 345: 1474-8.
12. Andersson HC, Charron J, Kaplan P, et al. Individualization of long-term enzyme replacement therapy for Gaucher disease. Genet Med 2005; 7: 105-10.
13. Cox TM, Lachmann R, Hollak C, et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000; 355: 1481-5.
14. Bach G, Friedman R, Weissmann B, Neufeld EF. The defect in the Hurler and Scheie syndromes: deficiency of -L-iduronidase. Proc Natl Acad Sci USA 1972; 69: 2048-51.
15. Guffon N, Souillet G, Maire I, et al. Follow-up of nine patients with Hurler syndrome after bone marrow transplantation. J Pediatr 1998; 133: 119-25.
16. Wraith JE, Clarke LA, Beck M, et al. Enzyme replacement therapy for mucopalysaccharidasis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 2004; 144: 581-8.
17. Kakkis E, Muenzer J, Tiller GE, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001; 344: 182-8.
18. Wraith JE, Hopwood J, Fuller M, et al. Laronidase treatment of mucopolysaccharidosis I. BioDrugs 2005; 19: 1-7.
19. Litjens T, Brooks DA, Peters C, et al. Identification, expression, and biochemical characterization of N-acetylgalactosamine-4-sulfatase mutations and relationship with clinical phenotype in MPS-VI patients. Am J Hum Genet 1996; 58: 1127-34.
20. Herskhovitz E, Young E, Rainer J, et al. Bone marrow transplantation for Maroteaux-Lamy syndrome (MPS VI): long-term follow-up. J Inherit Metab Dis 1999; 22: 50-62.
21. Harmatz P, Chester B, Whitley CB, et al. Enzyme replacement therapy in mucopolysaccharidasis VI (Maroteaux-Lamy syndrome). J Pediatr 2004; 144: 574-80.
22. Harmatz P, Ketteridge D, Giugliani R, et al. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 2005; 115: e681-9.
23. Galsulfase: arylsulfatase B, BM 102, recombinant human arylsulfatase B, recombinant human N-acetylgalactosamine-4-sulfatase, rhASB. Drugs RD 2005; 6: 312-5.
24. Dhami GK, Babwah AV, Sterne-Marr R, Ferguson SS. Mannose 6-phosphate receptor-mediated uptake is defective in acid sphingomyelinase-deficient macrophages: implications for Niemann-Pick disease enzyme replacement therapy. J Biol Chem 2004; 279: 1526-32.
25. Kishnani PS, Howell RR. Pompe disease in infants and children. J Pediatr 2004; 144: S3S-43.
26. Van den Haut H, Reuser AJJ, Vulto AG, et al. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 2000; 356: 397-8.
27. Klinge L, Straub U, Neudorf J, et al. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul Disord 2005; 15: 24-31.
28. Van den Hout JM, Kamphoven JH, Winkel LP, et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 2004; 113: e448-57.
29. Raben N, Fukuda T, Gilbert AL, et al. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. Mol Ther 2005; 11: 48-56.
30. Desnick RJ. Enzyme replacement and enhancement therapies for lysosomal diseases. J Inherit Metab Dis 2004; 27: 385-410.